Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Treatment involves selecting, multiplying and reinfusing cancer-fighting immune cells.
The results from an innovative, “virtual” clinical trial were presented at the 2019 ASCO Annual Meeting.
Targeted therapy combination reduced the risk of disease progression or death by 65% in a randomized study.
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life.
“The bladder cancer research community pulled together to get this trial done,” says principal investigator Thomas Flaig, MD.
Even positive breaking news looks different to people who know the reality of a hard-to-treat cancer.
RET inhibitor shrank tumors in more than half of people with non-small-cell lung cancer and aggressive thyroid cancer.
The test was able to identify many cancers, and their location, at early stages.
Researchers are continuing to identify potential biomarkers or specific clinical factors to identify the best candidates for treatments.
It is important to identify this need for sexual health support and address the gap in care with resources, says study author Lindsay Welton
Lynparza maintenance therapy after chemotherapy nearly doubled progression-free survival.
A Phase II trial reached its primary endpoint of overall response in just over a third of participants.
A Phase II trial tested SurVaxM in combination with standard therapy for the aggressive brain cancer.
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
Why the head of the world’s largest cancer organization braved dirt roads and crowded urban streets to reach impoverished cancer centers
Just 13% of men who opted for active surveillance over treatment adhered to the recommended monitoring schedule.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.